Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe

Expert Review of Vaccines

Volumn 8, Issue 10, 2009, Pages 1351-1364

  Rose, Markus ^a   Zielen, Stefan ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Immunization program; Infant; Pneumococcal conjugate vaccine; Prevention

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; MACROLIDE; PENICILLIN G; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE;

ACUTE OTITIS MEDIA; ANTIBIOTIC RESISTANCE; BODY TEMPERATURE; CHILD HEALTH CARE; CLINICAL TRIAL; DISEASE SURVEILLANCE; DRUG EFFICACY; DRUG SAFETY; EUROPE; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; MORBIDITY; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL MENINGITIS; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; REVIEW; SEROTYPE; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDER; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DISEASE OUTBREAKS; DRUG APPROVAL; EUROPE; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; INFANT; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PRACTICE GUIDELINES AS TOPIC; TIME FACTORS; UNITED STATES; VACCINES, CONJUGATE;

EID: 70349918172     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.09.78     Document Type: Review

References (89)

1. WHO position paper. Pneumococcal conjugate vaccine for childhood immunization. Wkly. Epidemiol. Rec. 82(12), 93-104 (2007).
2. Advisory Committee on Immunization Practices (ACIP). Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 49 (No.) (2000).
3. Williams BG, Gouws E, Boschi-Pinto C, Bryce J, Dye C. Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect. Dis. 2(1), 25-32 (2002).
4. Dowell SF, Schwartz B, Phillips WR. Appropriate use of antibiotics for URIs in children: part I. Otitis media and acute sinusitis. The Pediatric URI Consensus Team. Am. Fam. Physician 58(5), 1113-1118 (1998).
5. Pebody RG, Hellenbrand W, D'Ancona F, Ruutu P. Pneumococcal disease surveillance in Europe. Euro. Surveill. 11, 171-178 (2006).
6. Prymula R, Peeters P, Chrobok V et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable H. influenzae: a randomised double-blind efficacy study. Lancet 367 (9512), 740-748 (2006). • Demonstrates the efficacy of 11-valent pneumococcal vaccine conjugated to protein D as a reduction of clinical episodes of acute otitis media, culture-confirmed bacterial episodes, but also limits of efficacy against nontypeable Haemophilus influenzae. (Pubitemid 43326292)
7. Eskola J, Kilpi T, Palmu A et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl. J. Med. 344(6), 403-409 (2001). • Describes the vaccine efficacy for otitis media in the Finnish Otitis Media Vaccine, which was a large, randomized, controlled trial of seven-valent pneumococcal conjugate vaccine (PCV-7)-CRM197 and PCV-7 outer membrane protein complex.
8. Kilpi T, Herva E, Kaijalainen T, Syrjanen R, Takala AK. Bacteriology of acute otitis media in a cohort of Finnish children followed for the first two years of life. Pediatr. Infect. Dis. J. 20, 654-662 (2001).
9. Ess SM, Schaad UB, Gervaix A, Pinosch S, Szucs TD. Cost-effectiveness of a pneumococcal conjugate immunisation program for infants in Switzerland. Vaccine 21, 3273-3281 (2003). (Pubitemid 36694568)
10. Ziebold C, von Kries R, Siedler A, Schmitt HJ. Epidemiology of pneumococcal disease in children in Germany. Acta Paediatr. Suppl. 435, 17-21 (2000).
11. Brueggemann AB, Griffiths DT, Meats E et al. Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. J. Infect. Dis. 187, 1424-1432 (2003).
12. Rueckinger S, von Kries Ruediger, Reinert RR, van der Linden M, Siedler A. Childhood invasive pneumococcal disease in Germany between 1997 and 2003: variability in incidence and serotype distribution in absence of general pneumococcal conjugate vaccination. Vaccine 26, 3984-3986 (2008).
13. Jefferson T, Ferroni E, Curtale F, Giorgi Rossi P, Borgia P. S. pneumoniae in western Europe: serotype distribution and incidence in children less than 2 years old. Lancet Infect. Dis. 6(7), 405-410 (2006).
14. Pérez A, Herranz M, Segura M et al. Epidemiologic impact of blood culture practices and antibiotic consumption on pneumococcal bacteraemia in children. Eur. J. Clin. Microbiol. Infect. Dis. 27(8), 717-724 (2008).
15. Jourdain S, Smeesters P, Sputael V et al. Dynamic epidemiology of naso-pharyngeal flora in kindergarten children. Presented at: 6th International Symposium on Pneumococci & Pneumococcal Diseases. Reykjavik, Iceland, 8-12 June 2008.
16. Pérez Méndez C, Solís Sánchez G, Miguel Martínez D et al. Predictive factors for invasive pneumococcal disease: a case-control study. An. Esp. Pediatr. 57(4), 310-316 (2002).
17. Robinson KA, Baughman W, Rothrock G et al. Active Bacterial Core Surveillance (ABCs)/Emerging Infections Program Network. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA 285, 1729-1735 (2001).
18. Bernaola Iturbe E, Aristegui Fernández J, Herranz Aguirre M, García Calvo C, Fernández Pérez C; Grupo de Estudio de Enfermedad Invasora Neumococica en el Pais Vasco-Navarra. Study of the incidence of invasive pneumococcal disease in neonates and children aged less than 5 years in the Basque country and Navarre (Spain). An. Esp. Pediatr. 57, 301-309 (2002).
19. Casado Flores J, Fenoll A, Aristegui Fernández J et al. Grupo para el Estudio de la Meningitis Neumocócica. Pneumococcal meningitis in Spanish children: incidence, serotypes and antibiotic resistance. An. Esp. Pediatr. 57(4), 295-300 (2002).
20. McIntosh ED, Fritzell B, Fletcher MA. Burden of paediatric invasive pneumococcal disease in Europe, 2005. Epidemiol. Infect. 135(4), 644-656 (2007).
21. Vergison A, Tuerlinckx D, Verhaegen J, Malfroot A; Belgian Invasive Pneumococcal Disease Study Group. Epidemiologic features of invasive pneumococcal disease in Belgian children: passive surveillance is not enough. Pediatrics 118(3), e801-e809 (2006).
22. Eriksson M, Henriques B, Ekdahl K. Epidemiology of pneumococcal infections in Swedish children. Acta Paediatrica 89(Suppl. 435), 35-39 (2000). (Pubitemid 32039646)
23. Olivier C, Begne P, Cohen R, Floret D. Pneumococcal meningitis in children: results of a nationwide investigation (1993-1995). Wkly Epidemiol. Bull. 16, 67-69 (2000).
24. Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin. Infect. Dis. 30(1), 100-121 (2000). •• Summarizes serotype distribution in different geographical regions.
25. Edwards KM, Griffin MR. Great expectations for a new vaccine. N Engl. J. Med. 349(14), 1312-1314 (2003).
26. Dagan R, Givon-Lavi N, Zamir O et al. Reduction of nasopharyngeal carriage of S. pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J. Infect. Dis. 185(7), 927-936 (2002).
27. O'Brien KI, Dagan R. The potential indirect effects of conjugate pneumococcal vaccines. Vaccine 21, 1815-1825 (2003).
28. BlackS, Shinefield H, Fireman B et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr. Infect. Dis. J. 19, 187-195 (2000).
29. Black SB, Shinefield HR, Ling S et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr. Infect. Dis. J. 21(9), 810-815 (2002).
30. Cutts FT, Zaman SM, Enwere G et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 365(9465), 1139-1146 (2005). (Pubitemid 40417563)
31. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N. Engl. J. Med. 349(14), 1341-1348 (2003).
32. O'Brien KL, David AB, Chandran A et al. Randomized, controlled trial efficacy of pneumococcal conjugate vaccine against otitis media among Navajo and White Mountain Apache infants. Pediatr. Infect. Dis. J. 27(1), 71-73 (2008).
33. Palmu AA, Verho J, Jokinen J, Karma P, Kilpi TM. The seven-valent pneumococcal conjugate vaccine reduces tympanostomy tube placement in children. Pediatr. Infect. Dis. J. 23(8), 732-738 (2004).
34. Kilpi T, Ahman H, Jokinen J et al. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin. Infect. Dis. 37(9), 1155-1164 (2003).
35. Rose M, Krisch J, Sprenger R, Zielen S. Utilization and safety of sequential pneumococcal vaccination in 2-5 year old children at risk. Presented at: 26th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). Graz, Austria, 13-16 May 2008.
36. Rose M, Hey C, Kujumdshiew S, Gall V, Schubert R, Zielen S. Immunogenicity of pneumococcal vaccination in patients with cochlear implants. J. Infect. Dis. 190, 551-557 (2004).
37. Rose MA, Schubert R, Strnad N, Zielen S. Priming of immunological memory by pneumococcal conjugate vaccine in children unresponsive to 23-valent polysaccharide pneumococcal vaccine. Clin. Diagnost. Lab. Immunol. 12(10), 1216-1222 (2005).
38. Stoehr GA, Rose MA, Eber SW, Heidemann K, Schubert R, Zielen S. Immunogenicity of sequential pneumococcal vaccination in subjects splenectomised for hereditary spherocytosis. Br. J. Haematol. 132(6), 788-790 (2006).
39. van der Linden M, Reinert RR. Effects of the national immunization programme for PCV-7 on IPD in children in Germany. Presented at: 26th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). Graz, Austria, 13-16 May 2008.
40. Vestrheim DF, Lovoll O, Aaberge IS et al. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine 26(26), 3277-3281 (2008). • Demonstrates effectiveness of a 2+1 PCV-7 schedule in Europe.
41. Lepoutre A, Varan E, Georges S, Gutmann L, Lévy-Bruhl D. Impact of infant pneumococcal vaccination on invasive pneumococcal disease in France. Eurosurveillance 13(35), 1-6 (2008).
42. Bingen E, Levy C, Varon E et al. Pneumococcal meningitis in the era of pneumococcal conjugate vaccine implementation. Eur. J. Clin. Microbiol. Infect. Dis. 27(3), 191-199 (2008).
43. Dubos F, Marechal I, Husson MO et al. Decline in pneumococcal meningitis after the introduction of the heptavalent pneumococcal conjugate vaccine in northern France. Arch. Dis. Child. 92(11), 1009-1012 (2007).
44. Foster D, Knox K, Walker AS et al. Oxford Invasive Pneumococcal Surveillance Group Invasive pneumococcal disease: epidemiology in children and adults prior to implementation of the conjugate vaccine in the Oxfordshire region, England. J. Med. Microbiol. 57(Pt 4), 480-487 (2008).
45. Kaye P, Andrews N, Slack M, George R, Miller E. Vaccine effectiveness and indirect protection from pneumococcal conjugate vaccine used in a 2 dose infant priming plus booster schedule in England and Wales. Presented at: 6th International Symposium on Pneumococci & Pneumococcal Diseases. Reykjavik, Iceland, 8-12 June 2008.
46. Hanquet G, Kissling E, Tarragó D et al. Dynamic changes of three non-vaccine pneumococcal serotypes in Spain, France, Belgium and England & Wales, 1996-2006. Presented at: 6th International Symposium on Pneumococci & Pneumococcal Diseases. Reykjavik, Iceland, 8-12 June 2008.
47. Aristegui J, Bernaola E, Pocheville I et al. Reduction in pediatric invasive pneumococcal disease in the Basque Country and Navarre, Spain, after introduction of the heptavalent pneumococcal conjugate vaccine. Eur. J. Clin. Microbiol. Infect. Dis. 26(5), 303-310 (2007).
48. Oteo J, Lazaro E, de Abajo FJ, Baquero F, Campos J; Spanish members of the European Antimicrobial Resistance Surveillance System. Trends in antimicrobial resistance in 1,968 invasive S. pneumoniae strains isloted in Spanish hospitals 2001-2003: decreasing penicillin resistance in children's isolates. J. Clin. Microbiol. 42, 5571-5577 (2004).
49. Calbo E, Díaz A, Cafiadell E et al.; Spanish Pneumococcal Infection Study Network. Invasive pneumococcal disease among children in a health district of Barcelona: early impact of pneumococcal conjugate vaccine. Clin. Microbiol. Infect. 12, 867-872 (2006).
50. Obando I, Arroyo LA, Sánchez-Tatay D et al. Molecular epidemiology of paediatric invasive pneumococcal disease in southern Spain after the introduction of heptavalent pneumococcal conjugate vaccine. Clin. Microbiol. Infect. 3(3), 347-348 (2007).
51. Dias R, Canica M. Invasive pneumococcal disease in Portugal prior to and after the introduction of pneumococcal heptavalent conjugate vaccine. FEMS Immunol. Med. Microbiol. 51(1), 35-42 (2007).
52. Aguiar SI, Serrano I, Pinto FR, Melo-Cristino J, Ramirez M; Portuguese Surveillance Group for the Study of Respiratory Pathogens. Changes in Streptococcus pneumoniae serotypes causing invasive disease with non-universal vaccination coverage of the seven-valent conjugate vaccine. Clin. Microbiol. Infect. 14(9), 835-843 (2008).
53. Esposito S, Liziolo A, Lastrico A et al. Impact on respiratory tract infections of heptavalent pneumococcal conjugate vaccine administered at 3, 5, and 11 months of age. Respir. Res. 8(12), 1-9 (2007).
54. Ansaldi F, Sticchi L, Durando P et al. Decline in pneumonia and acute otitis media after the introduction of childhood pneumococcal vaccination in Liguria, Italy. J. Int. Med. Res. 36(6), 1255-1260 (2008).
55. Zissis NP, Syriopoulou V, Kafetzis D et al. Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae causing invasive infections and acute otitis media in children. Eur. J. Pediatr. 163, 364-368 (2004).
56. Levidiotou S, Vrioni G, Tzanakaki G et al. Serotype distribution of Streptococcus pneumoniae in north-western Greece and implications for a vaccination programme. FEMS Immunol. Med. Microbiol. 48, 179-182 (2006).
57. Grivea IN, Panagiotou M, Tsantouli AG, Syrogiannopoulos GA. Impact of heptavalent pneumococcal conjugate vaccine on nasopharyngeal carriage of penicillin-resistant S. pneumoniae among day-care center attendees in central Greece. Pediatr. Infect. Dis. J 27(6), 519-525 (2008).
58. Fenoll A, Jado I, Vicioso D, Berron S, Yuste JE, Casal J. Streptococcus pneumoniae in children in Spain: 1990-1999. Acta Paediatr. Suppl. 435, 44-50 (2000).
59. Adam D, Fehnle K. Safety and effectiveness against respiratory react infections for pneumococcal conjugate vaccine co-administered with routine vaccine combinations. Vaccine 26(47), 5944-5951 (2008).
60. van Kempen MJ, Vermeiren JS, Vaneechoutte M et al. Pneumococcal conjugate vaccination in children with recurrent acute otitis media: a therapeutic alternative? Int. J. Pediatr. Otorhinolaryngol. 70(2), 275-285 (2006).
61. Veenhoven R, Bogaert D, Uiterwaal C et al. Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study. Lancet 361(9376), 2189-2195 (2003). (Pubitemid 36782552)
62. van Heerbeek N, Straetemans M, Wiertsema SP et al. Effect of combined pneumococcal conjugate and polysaccharide vaccination on recurrent otitis media with effusion. Pediatrics 117(3), 603-608 (2006). (Pubitemid 46063199)
63. Cohen R, Levy C, de la Rocque F et al. Impact of pneumococcal conjugate vaccine and of reduction of antibiotic use on nasopharyngeal carriage of nonsusceptible pneumococci in children with acute otitis media. Pediatr. Infect. Dis. J. 25(11), 101-107 (2006).
64. Moore MR, Gertz REJ, Woodbury RI et al. Population snapshot of emergent S. pneumoniae 19A in the United States. J. Infect. Dis. 197, 1016-1027 (2005).
65. Pelton SI, Huot H, Finkelstein JA et al. Emergence of 19A as virulent and multidrug resistant pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J 26(6), 468-472 (2007).
66. Pai R, Moore MR, Pilishvili T, Gertz RE, Whitney CG, Beall B. Postvaccine genetic structure ofStreptococcus pneumoniae serotype 19A from children in the United States. J. Infect. Dis. 192(11), 1988-1995 (2005).
67. Coffey TJ, Enright MC, Daniels M et al. Recombinant exchanges at the capsular polysaccharide biosynthetic locus lead to frequent serotype changes among natural isolates of S. pneumoniae. Mol. Microbiol. 27, 73-83 (1998).
68. Termine L, Boelle PY, Opatowski L, Guillemot D. Impact of capsular switch on invasive pneumococcal disease incidence in a vaccinated population. PLoS ONE 3(9), 1-9 (2008). • Explains pneumococcal antibiotic resistance mechanisms.
69. Rückinger S, von Kries R, Siedler A, van der Linden M. Association of serotype of Streptococcus pneumoniae with risk of severe and fatal outcome. Pediatr. Infect. Dis. J. 28(2), 118-122 (2009).
70. Lipsitch M. Bacterial vaccines and serotype replacement: lessons from H. influenzae and prospects for S. pneumoniae. Emerg. Infect. Dis. 5(3), 336-345 (1999).
71. Hwa Choi E, Hee Kim S, Wook Eun B et al. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg. Infect. Dis. 14(2), 275-281 (2008). • Demonstrates the increased incidence of serotype 19A before the introduction of PCV-7 in South Korea.
72. Cohen R, Levy C, Thollot F et al. Pneumococcal conjugate vaccine does not influence S. aureus carriage in young children with otitis media. Clin. Infect. Dis. 45, 1583-1587 (2007).
73. Hicks LA, Harrison LH, Flannery B et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV-7) serotypes in the US during the era of widespread PCV-7 vaccination, 1998-2004. J. Infect. Dis. 196, 1346-1354 (2007).
74. Knuf M, Habermehl P, Cimino C, Petersen G, Schmitt HJ. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV-7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants. Vaccine 24(22), 4727-4736 (2006).
75. Chevallier B, Vesikari T, Brzostek J et al. Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines. Pediatr. Infect. Dis. J. 28(4 Suppl.), S109-S118 (2009).
76. Barricarte A, Castilla J, Gil-Setas A et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine: a population-based case-control study. Clin. Infect. Dis. 44(11), 1436-1441 (2007).
77. Lernout T, Hanquet G, Verhaegen J. Epidemiology of invasive pneumococcal disease after introduction of the conjugate vaccine: the Belgian experience. Presented at: 6th International Symposium on Pneumococci & Pneumococcal Diseases. Reykjavik, Iceland, 8-12 June 2008.
78. Munoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-Garcia JJ, Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin. Infect. Dis. 46(2), 174-182 (2008).
79. van der Ende A, Spanjaard L. The epidemiology of invasive pneumococcal disease in The Netherlands one year after the introduction of the heptavalent pneumococcal conjugate vaccine. Presented at: 6th International Symposium on Pneumococci & Pneumococcal Diseases, Reykjavik, Iceland, 8-12 June 2008.
80. Brouwer CN, Maillé AR, Rovers MM et al. Effect of pneumococcal vaccination on quality of life in children with recurrent acute otitis media: a randomized, controlled trial. Pediatrics 115(2), 273-279 (2005).
81. Le TM, Rovers MM, Veenhoven RH, Sanders EA, Schilder AG. Effect of pneumococcal vaccination on otitis media with effusion in children older than 1 year. Eur. J. Pediatr. 166(10), 1049-1052 (2007).
82. Palmu AAI, Jokinen JT, Kaijalainen T, Leinonen M, Karma P, Kilpi TM. Association of clinical signs and symptoms with pneumococcal acute otitis media by serotype -implications for vaccine effect. Clin. Infect. Dis. 40, 52-57 (2005).
83. European Centre for Disease Prevention and Control http://ecdc.europa.eu
84. Noah N, Henderson B. Surveillance of bacterial meningitis in Europe 1999/2000. Communicable Disease Surveillance Center, Public Health Laboratory Service, London, United Kingdom (2002). www.hpa.org.uk/hpa/inter/m- surveillance9900.pdf
85. WHO: Strategic Advisory Group of Experts (SAGE) on Immunization www.who.int/immunization/sage
86. Health Protection Agency www.hpa.org.uk
87. Eur-lex: Access to European Union Law http://eur-lex.europa.eu/LexUriServ
88. Eurosurveillance www.eurosurveillance.org
89. The European Antimicrobial Resistance Surveillance System www.earss.rivm.nl